2022
Treatment Outcomes for Radiation Therapy with Concurrent Carboplatin and Paclitaxel for Locally Advanced Head and Neck Cancer
Han J, Zakeri K, Raab G, Chen L, Yu Y, Kang J, McBride S, Riaz N, Tsai C, Gelblum D, Sherman E, Wong R, Michel L, Lee N. Treatment Outcomes for Radiation Therapy with Concurrent Carboplatin and Paclitaxel for Locally Advanced Head and Neck Cancer. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e317. DOI: 10.1016/j.ijrobp.2022.07.1381.Peer-Reviewed Original ResearchProgression-free survivalCisplatin-ineligible patientsDefinitive radiation therapyUnknown primary cancerLocoregional controlRadiation therapyDistant controlConcurrent carboplatinWeekly carboplatinAdvanced headOverall survivalHNSCC patientsPrimary cancerNeck squamous cell carcinomaConclusions Radiation therapyConsecutive HNSCC patientsCycles of chemotherapySevere ulcerative colitisUpper gastrointestinal bleedMedian radiation doseSynchronous primary malignanciesKaplan-Meier methodSquamous cell carcinomaMATERIAL/METHODSCumulative incidence function
2021
TERT Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence
Yu Y, Fan D, Song X, Zakeri K, Chen L, Kang J, McBride S, Tsai CJ, Dunn L, Sherman E, Katabi N, Dogan S, Cracchiolo J, Cohen M, Boyle JO, Lee M, Valero C, Wang J, Wong R, Morris L, Riaz N, Lee N. TERT Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence. JCO Precision Oncology 2021, 5: 1259-1269. PMID: 34381934, PMCID: PMC8345918, DOI: 10.1200/po.20.00515.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaLocoregional failurePatterns of failureCumulative incidenceCell carcinomaPromoter mutationsHPV-positive oropharyngeal squamous cell carcinomaMemorial Sloan-Kettering Cancer CenterRisk of LRFOropharyngeal squamous cell carcinomaNeck squamous cell carcinomaHPV-negative HNSCCsReverse transcriptase (TERT) promoter mutationsOral cavity cancerNext-generation sequencingTERT promoter mutationsDisease subsiteLocoregional recurrenceOverall cohortOverall survivalProspective cohortCancer CenterHuman papillomavirusLaryngopharyngeal cancerUnique pathogenesis
2019
Platinum‐based regimens versus cetuximab in definitive chemoradiation for human papillomavirus‐unrelated head and neck cancer
Beckham TH, Barney C, Healy E, Wolfe AR, Branstetter A, Yaney A, Riaz N, McBride SM, Tsai CJ, Kang J, Yu Y, Chen L, Sherman E, Dunn L, Pfister DG, Tan J, Rupert R, Bonomi M, Zhang Z, Lobaugh SM, Grecula JC, Mitchell DL, Wobb JL, Miller ED, Blakaj DM, Diavolitsis VM, Lee N, Bhatt AD. Platinum‐based regimens versus cetuximab in definitive chemoradiation for human papillomavirus‐unrelated head and neck cancer. International Journal Of Cancer 2019, 147: 107-115. PMID: 31609479, DOI: 10.1002/ijc.32736.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCetuximabChemoradiotherapyCisplatinFemaleHead and Neck NeoplasmsHumansMaleMiddle AgedNeoplasm StagingPapillomaviridaePapillomavirus InfectionsRandomized Controlled Trials as TopicSquamous Cell Carcinoma of Head and NeckSurvival RateConceptsLocoregional failureOverall survivalDistant metastasisReduced hazardMultivariable analysisKaplan-MeierHuman papillomavirus-unrelated headNeck squamous cell carcinomaPlatinum-based regimensSquamous cell carcinomaSuperior locoregional controlCumulative incidence functionDefinitive chemoradiationDefinitive radiotherapyLocoregional controlAdvanced headClinical characteristicsCumulative incidenceConcurrent cetuximabPropensity matchingYear OSCell carcinomaHuman papillomavirusNeck cancerProportional hazardsA retrospective analysis of cisplatin dosing strategies when used with radiation on outcomes in head and neck squamous cell carcinoma of the oropharynx.
Tchekmedyian V, Ho A, Dunn L, Fetten J, Pfister D, Lobaugh S, Zhang Z, Kang J, Chen L, Riaz N, McBride S, Yu Y, Tsai C, Lee N, Sherman E. A retrospective analysis of cisplatin dosing strategies when used with radiation on outcomes in head and neck squamous cell carcinoma of the oropharynx. Journal Of Clinical Oncology 2019, 37: 6079-6079. DOI: 10.1200/jco.2019.37.15_suppl.6079.Peer-Reviewed Original ResearchHPV/p16 statusOverall survivalRetrospective analysisTotal doseT stageP16 statusMultivariate Cox proportional hazards modelMultivariate analysisMedian f/uCox proportional hazards regressionCox proportional hazards modelNeck squamous cell carcinomaHPV/p16Start of RTProportional hazards regressionSquamous cell carcinomaSplit-dose administrationProportional hazards modelCI dosingPrimary CRTInduction chemotherapyCRT outcomesDistant failureProspective trialMedian age